This issue brief presents recent data on prevalence of opioid misuse and death rates in the Black/AA population; contextual factors & challenges to prevention & treatment; innovative outreach & engagement strategies to connect people to evidence-based treatment; and the importance of community voice.
You May Also Be Interested In
This handbook provides guidance on using the web-based, multimedia tool Decisions in Recovery: Medications for Opioid Addiction. This handbook and the web-based tool offers information about medication-assisted treatment. Both resources help people living with opioid use disorder compare treatment options and discuss their preferences with a provider.
Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide
This guide explains how to use extended-release injectable naltrexone as part of medication-assisted treatment (MAT) for opioid use disorder. It covers assessing patients, initiating MAT, monitoring progress, and deciding when to end treatment.
This guide provides information for African American consumers on the link between HIV/AIDS and substance use. It explains the increased risk of HIV transmission and the importance of treatment for alcohol and substance misuse and HIV/AIDS.
This item comes in packs of 50.
This guide highlights the use of medication-assisted treatment (MAT) for opioid use disorder in drug courts. It reviews effective medications, including methadone, buprenorphine, and naltrexone. The guide also provides strategies to increase the use of MAT in drug court programs.
Advisory: An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People with Opioid Dependence
This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.
This report presents information about Medicaid coverage of medication-assisted treatment for opioid and alcohol dependence. It covers treatment effectiveness and cost effectiveness. The report also offers examples of innovative approaches in Vermont, Massachusetts, and Maryland.